<code id='1CC7226296'></code><style id='1CC7226296'></style>
    • <acronym id='1CC7226296'></acronym>
      <center id='1CC7226296'><center id='1CC7226296'><tfoot id='1CC7226296'></tfoot></center><abbr id='1CC7226296'><dir id='1CC7226296'><tfoot id='1CC7226296'></tfoot><noframes id='1CC7226296'>

    • <optgroup id='1CC7226296'><strike id='1CC7226296'><sup id='1CC7226296'></sup></strike><code id='1CC7226296'></code></optgroup>
        1. <b id='1CC7226296'><label id='1CC7226296'><select id='1CC7226296'><dt id='1CC7226296'><span id='1CC7226296'></span></dt></select></label></b><u id='1CC7226296'></u>
          <i id='1CC7226296'><strike id='1CC7226296'><tt id='1CC7226296'><pre id='1CC7226296'></pre></tt></strike></i>

          Home / explore / hotspot

          hotspot


          hotspot

          author:focus    Page View:461
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In